Aminoglycoside toxicity in neonates: Something to worry about?

Expert Review of Anti-Infective Therapy

Volumn 12, Issue 3, 2014, Pages 319-331

  Kent, Alison ^a   Turner, Mark A ^b   Sharland, Mike ^a   Heath, Paul T ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

amikacin; aminoglycoside; gentamicin; multiple daily doses; neonatal; nephrotoxicity; once daily dosing; ototoxicity; pediatric

Indexed keywords

AMIKACIN; AMINOGLYCOSIDES; ANIMALS; ANTI-INFECTIVE AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EAR, INNER; GENTAMICINS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFANT, NEWBORN; KIDNEY;

EID: 84894189265     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2014.878648     Document Type: Review

References (114)

1. Muller-Pebody B, Johnson AP, Heath PT, et al. Empirical treatment of neonatal sepsis: are the current guidelines adequate? Arch Dis Child Fetal Neonatal Ed 2011;96(1):F4-8
2. Turner MA, Lewis S, Hawcutt DB, Field D. Prioritising neonatal medicines research: UK Medicines for Children Research Network scoping survey. BMC Pediatr 2009;9:50
3. National Institute of Health and Care Excellence. Antibiotics for Early Onset Neonatal Infection August 2012.
4. Mims C, Playfair J, Roitt I, et al. Medical microbiology. 2nd edition. Mosby, Inc. London, UK; 1998. p. 419-22
5. Quiros Y, Vicente-Vicente L, Morales AI, et al. An integrative overview on the mechanisms underlying the renal tubular cytotoxicity of gentamicin. Toxicol Sci 2011;119(2):245-56
6. Pacifici GM. Clinical pharmacokinetics of aminoglycosides in the neonate: a review. Eur J Clin Pharmacol 2009;65(4):419-27
7. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 1997;39(6):677-86
8. Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 2012(2):CD002009
9. Mavros MN, Polyzos KA, Rafailidis PI, Falagas ME. Once versus multiple daily dosing of aminoglycosides for patients with febrile neutropenia: a systematic review and meta-analysis. J Antimicrob Chemother 2011;66(2):251-9
10. BNF for children. Available from: www.BNF.org [Last accessed 13 November 2013]
11. Madsen L, Rasmussen M, Bjerregaard L, et al. Impact of blood sampling in very preterm infants. Scand J Clin Lab Invest 2000;60(2):125-32
12. Kahlmeter G, Dahlager JI. Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother 1984;13(Suppl A):9-22
13. Contopoulos-Ioannidis DG, Giotis ND, Baliatsa D V, et al. Extended-interval aminoglycoside administration for children. Pediatrics 2004;114(1):e111-18
14. Pullens B, Van Benthem PP. Intratympanic gentamicin for Ménière's disease or syndrome. Cochrane Database Syst Rev 2011(3):CD008234
15. Hawkins JE, Lurie MH. The ototoxicity of streptomycin. Trans Am Otol Soc 1952;40:133-53
16. Heck WE, Hinshaw HC, Parsons HG. Auditory ototoxicity in tuberulous patients treated with a report of the incidence of hearing loss in a series of 1150 cases. JAMA 1963;186:18-20
17. Jawetz E. Neomycin ototoxicity: dossier and dosage. N Engl J Med 1969;281(4):219
18. McCracken GH. Aminoglycoside toxicity in infants and children. Am J Med 1986;80(6 B):172-8
19. Brummett RE, Fox KE, Bendrick TW, Himes DL. Ototoxicity of tobramycin, gentamicin, amikacin and sisomicin in the guinea pig. J Antimicrob Chemother 1978;4(Suppl A):73-83
20. Dulon D, Aran JM, Zajic G, Schacht J. Comparative uptake of gentamicin, netilmicin, and amikacin in the guinea pig cochlea and vestibule. Antimicrob Agents Chemother 1986;30(1):96-100
21. Dahlgren JG, Anderson ET, Hewitt WL. Gentamicin Blood Levels: a Guide to Nephrotoxicity. Antimicrob Agents Chemother 1975;3:202-15
22. Moore RD, Smith CR, Lietman PS. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis 1984;149(1):23-30
23. Fee W. Aminoglycoside ototoxicity in the human. Larynogoscope 1980;90(Supp 24):1-9
24. Black RE, Lau WK, Ralph J, et al. Ototoxicity of Amikacin. Antimicrob Agents Chemother 1976;9:956-61
25. Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des 2007;13(1):119-26
26. Rybak LP, Ramkumar V. Ototoxicity. Kidney Int 2007;72(8):931-5
27. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000;103(2):239-52
28. Li H, Wang Q, Steyger PS. Acoustic trauma increases cochlear and hair cell uptake of gentamicin. PLoS One 2011;6(4):e19130
29. Huth ME, Ricci A J, Cheng A G. Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolaryngol 2011;2011:937861
30. Corbacella E, Lanzoni I, Ding D, et al. Minocycline attenuates gentamicin induced hair cell loss in neonatal cochlear cultures. Hear Res 2004;197(1-2):11-18
31. Tran Ba Huy P, Manuel C, Meulemans A, et al. Pharmacokinetics of gentamicin in perilymph and endolymph of the rat as determined by radioimmunoassay. J Infect Dis 1981;143(3):476-86
32. Assael B, Parini R, Rusconi F. Ototoxicity of aminoglycoside antibiotics in infants and children. Pediatr Infect Dis 1982;1(5):357-65
33. Bernard P. Freedom from ototoxicity in aminoglycoside treated neonates: a mistaken notion. Laryngoscope 1981;91(12):1985-94
34. Zorowka P, Schmitt HJ, Eckel HE, et al. Serial measurements of transient evoked otoacoustic emissions (TEOAEs) in healthy newborns and in newborns with perinatal infection. Int J Pediatr Otorhinolaryngol 1993;27(3):245-54
35. Finitzo-Hieber T, Mccraeken GH, Brown KC. Prospective controlled evaluation of auditory function in neonates given netilmicin or amikacin. J Pediatrics 1985;106(1):129-36
36. Jacobson J, Jacobson C. Evaluation of hearing loss in infants and young children. Pediatr Ann 2004;33(12):811-21
37. Yoon PJ, Price M, Gallagher K, et al. The need for long-term audiologic follow-up of neonatal intensive care unit (NICU) graduates. Int J Pediatr Otorhinolaryngol 2003;67(4):353-7
38. Village EG. Newborn and Infant Hearing Loss: detection and Intervention. Pediatrics 1999;103(2):527-30
39. Vohr BR, Widen JE, Cone-Wesson B, et al. Identification of neonatal hearing impairment: characteristics of infants in the neonatal intensive care unit and well-baby nursery. Ear Hear 2000;21(5):373-82
40. Halpern J, Hosford-Dunn H, Malachowski N. Four factors that accurately predict hearing loss in "high risk" neonates. Ear Hear 1987;8(1):21-5
41. Cone-Wesson B, Vohr BR, Sininger YS, et al. Identification of neonatal hearing impairment: infants with hearing loss. Ear Hear 2000;21(5):488-507
42. Coenraad S, Goedegebure A, Van Goudoever JB, Hoeve LJ. Risk factors for sensorineural hearing loss in NICU infants compared to normal hearing NICU controls. Int J Pediatr Otorhinolaryngol 2010;74(9):999-1002
43. De Hoog M, Van Zanten BA, Hop WC, et al. Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss. J Pediatr 2003;142(1):41-6
44. Abramovich SJ, Gregory S, Slemick M, Stewart A. Hearing loss in very low birthweight infants treated with neonatal intensive care. Arch Dis Child 1979;54(6):421-6
45. Stavroulaki P, Apostolopoulos N, Dinopoulou D, et al. Otoacoustic emissions-an approach for monitoring aminoglycoside induced ototoxicity in children. Int J Pediatr Otorhinolaryngol 1999;50(3):177-84
46. Kumana C, Yuen K. Parental aminoglycoside therapy. Selection, administration and monitoring. Drugs 1994;47(6):902-13
47. Salamy A, Eldredge L, Tooley WH. Neonatal status and hearing loss in high-risk infants. J Pediatr 1989;114(5):847-52
48. Lane A Z, Wright GE, Blair DC. Ototoxicity and nephrotoxicity of amikacin: an overview of phase II and phase III experience in the United States. Am J Med 1977;62(6):911-18
49. Itsarayoungyuen S, Riff L, Schauf V, et al. Tobramycin and gentamicin are equally safe for neonates: results of a double-blind randomized trial with quantitative assessment of renal function. Pediatric Pharmacol 1982;2(2):143-55
50. De Hoog M, Van Zanten GA, Hoeve LJ, et al. A pilot case control follow-up study on hearing in children treated with tobramycin in the newborn period. Int J Pediatr Otorhinolaryngol 2002;65(3):225-32
51. Rao S, Srinivasjois R, Hagan R, Ahmed M. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates (Review). Cochrane Database Syst Rev 2011(1):CD005091
52. Robertson CMT, Howarth TM, Bork DLR, Dinu I A. Permanent bilateral sensory and neural hearing loss of children after neonatal intensive care because of extreme prematurity: a thirty-year study. Pediatrics 2009;123(5):e797-807
53. Brummett R. Effects of antibiotic-diuretic interactions in the guinea pig model of ototoxicity. Rev Infect Dis 1981;3:S216-23
54. Brown JJ, Brummett RE, Meikle MB, Vernon J. Combined effects of noise and neomycin. Cochlear changes in the guinea pig. Acta Otolaryngologica 1978;86(5-6):394-400
55. Li H, Steyger P. Synergistic ototoxicity due to noise exposure and aminoglycoside antibiotics. Noise Health 2009;11(42):26-32
56. Lasky RE, Williams AL. Noise and light exposures for extremely low birth weight newborns during their stay in the neonatal intensive care unit. Pediatrics 2009;123(2):540-6
57. Fischel-Ghodsian N. Mitochondrial deafness mutations reviewed. Hum Mutat 1999;13(4):261-70
58. Fischel-ghodsian N, Prezant TR, Chaltraw WE, et al. Mitochondrial predisposing gene mutation is a significant factor in aminoglycoside ototoxicity. Am J Otolaryngol 1997;18(3):173-8
59. Fischel-Ghodsian N. Genetic factors in aminoglycoside toxicity. Pharmacogenomics 2005;6(1):27-36
60. Hutchin T, Haworth I, Higashi K, et al. A molecular basis for human hypersensitivity to aminoglycoside antibiotics. Nucleic Acids Res 1993;21(18):4174-9
61. Hobbie SN, Akshay S, Kalapala SK, et al. Genetic analysis of interactions with eukaryotic rRNA identify the mitoribosome as target in aminoglycoside ototoxicity. Proc Natl Acad Sci USA 2008;105(52):20888-93
62. Qian Y, Guan M-X. Interaction of aminoglycosides with human mitochondrial 12S rRNA carrying the deafness-associated mutation. Antimicrob Agents Chemother 2009;53(11):4612-18
63. Arnos K, Xia X, Norris J. Relative frequencies of the mitochondrial A1555G and 961 delT mutations in the 12SrRNA gene from a large sample of deaf probands from the United States. Am Soc Hum Gen 2003; Abstract 2196
64. Estivill X, Govea N, Barceló E, et al. Familial progressive sensorineural deafness is mainly due to the mtDNA A1555G mutation and is enhanced by treatment of aminoglycosides. Am J Hum Genet 1998;62(1):27-35
65. Roland P. New developments in our understanding of ototoxicity. Ear Nose Throat J 2004;83(9 Suppl):15-16
66. Bitner-Glindzicz M, Pembrey M, Duncan A, et al. Prevalence of mitochondrial 1555A->G mutation in European children. N Engl J Med 2009;360(6):640-2
67. Ding Y, Leng J, Fan F, et al. The role of mitochondrial DNA mutations in hearing loss. Biochem Genet 2013;51(7-8):588-602
68. Tang H, Hutcheson E, Neill S, Drummond-Borg M. Genetic susceptibility to aminoglycoside ototoxicity: How many are at risk? Genet Med 2002;4(5):336-45
69. Casano R, Johnson D, Bykhovskaya Y, et al. Inherited susceptibility to aminoglycoside ototoxicity: genetic heterogeneity and clinical implications. Am J Otolaryngol 1999;20(3):151-6
70. Johnson RF, Cohen AP, Guo Y, et al. Genetic mutations and aminoglycosideinduced ototoxicity in neonates. Otolaryngol Head Neck Surg 2010;142(5):704-7
71. Boyle EM, Brookes I, Nye K, et al. "Random" gentamicin concentrations do not predict trough levels in neonates receiving once daily fixed dose regimens. BMC Pediatr 2006;6:8
72. Tomlinson RJ, Ronghe M, Goodbourne C, et al. Once daily ceftriaxone and gentamicin for the treatment of febrile neutropenia. Arch Dis Child 1999;80(2):125-31
73. Bas E, Van De Water TR, Gupta C, et al. Efficacy of three drugs for protecting against gentamicin-induced hair cell and hearing losses. Br J Pharmacol 2012;166(6):1888-904
74. Park MK, Lee BD, Chae SW, et al. Protective effect of NecroX, a novel necroptosis inhibitor, on gentamicininduced ototoxicity. Int J Pediatr Otorhinolaryngol 2012;76(9):1265-9
75. Fetoni AR, Eramo SLM, Rolesi R, et al. Antioxidant treatment with coenzyme Q-ter in prevention of gentamycin ototoxicity in an animal model. Acta Otorhinolaryngol Ital 2012;32(2):103-10
76. Berkiten G, Salturk Z, Topaloǧlu I, Uǧraş H. Protective effect of pentoxifylline on amikacin-induced ototoxicity in rats. Am J Otolaryngol 2012;33(6):689-92
77. Jankauskas SS, Plotnikov EY, Morosanova MA, et al. Mitochondriatargeted antioxidant SkQR1 ameliorates gentamycin-induced renal failure and hearing loss. Biochemistry 2012;77(6):666-70
78. Chen Y, Huang W-G, Zha D-J, et al. Aspirin attenuates gentamicin ototoxicity: from the laboratory to the clinic. Hear Res 2007;226(1-2):178-82
79. Matz G. Aminoglycoside ototoxicity. Am J Otolaryngol 1986;7(2):117-19
80. Luft FC. Clinical significance of renal changes engendered by aminoglycosides in man. J Antimicrob Chemother 1984;13(Suppl A):23-30
81. Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 1999;43(5):1003-12
82. Nagai J, Takano M. Review molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab Pharmacokinet 2004;19(3):159-70
83. Schreuder MF, Bueters RRG, Allegaert K. The interplay between drugs and the kidney in premature neonates. Pediatric Nephrol (Berlin, Germany) 2013. [Epub ahead of print]
84. Allegaert K, Langhendries JP, Van Den Anker JN. Educational paper: do we need neonatal clinical pharmacologists? Eur J Pediatr 2013;172(4):429-35
85. Provoost A, Adejuyigbe O, Wolff E. Nephrotoxicity of aminoglycosides in young and adult rats. Pediatr Res 1985;19(11):1191-6
86. Cowan R, Jukkola A, Arant B. Pathophysiologic evidence of gentamicin nephrotoxicity in neonatal puppies. Pediatr Res 1980;14:1204-11
87. Kunin C, Chesney R, Craig W, et al. Enzymuria as a marker of renal injury and disease: studies of N-acetyl-betaglucosaminidase in the general population and in patients with renal disease. Pediatrics 1978;62:751-60
88. Mohammadi-Karakani A, Asgharzadeh-Haghighi S, Ghazi-Khansari M, et al. Enzymuria determination in children treated with aminoglycosides drugs. Hum Exp Toxicol 2008;27(12):879-82
89. Zaffanello M, Brugnara M, Bruno C, et al. Renal function and volume of infants born with a very low birth-weight: a preliminary cross-sectional study. Acta Paediatrica (Oslo, Norway: 1992) 2010;99(8):1192-8
90. Giapros VI, Papadimitriou FK, Andronikou SK. Tubular disorders in low birth weight neonates after prolonged antibiotic treatment. Neonatology 2007;91(2):140-4
91. Giapros VI, Andronikou SK, Cholevas VI, Papadopoulou ZL. Renal function and effect of aminoglycoside therapy during the first ten days of life. Pediatric Nephrol (Berlin Germany) 2003;18(1):46-52
92. Vieux R, Fresson J, Guillemin F, Hascoet JM. Perinatal drug exposure and renal function in very preterm infants. Archiv Dis Child Fetal Neonatal Ed 2011;96(4):F290-5
93. McWilliam SJ, Antoine DJ, Sabbisetti V, et al. Mechanism-based urinary biomarkers to identify the potential for aminoglycosideinduced nephrotoxicity in premature neonates: a proof-of-concept study. PLoS One 2012;7(8):e43809
94. Cuzzolin L, Fanos V, Pinna B, et al. Postnatal renal function in preterm newborns: a role of diseases, drugs and therapeutic interventions. Pediatric Nephrol (Berlin, Germany) 2006;21(7):931-8
95. Martíinková L J, Pokorná L P, Záhora J, et al. Tolerability and outcomes of kinetically guided therapy with gentamicin in critically ill neonates during the first week of life: an open-label, prospective study. Clin Ther 2010;32(14):2400-14
96. Lundergan FS, Glasscock GF, Kim EH, Ronald S. Once-daily gentamicin dosing in newborn infants. Pediatrics 1999;103:1228-34
97. Peake M, Whiting M. Measurement of serum creatinine.current status and future goals. Clin Biochem Rev 2006;27(4):173-84
98. Skopnik H, Troster K, Heimann G, et al. Pharmacokinetics and antibacterial activity of daily gentamicin. Arch Dis Child 1992;8(67):57-61
99. Rastogi A, Agarwal G, Pyati S, Pildes RS. Comparison of two gentamicin dosing schedules in very low birth weight infants. Pediatr Infect Dis J 2002;21(3):234-40
100. De Alba Romero C, Gomez Castillo E, Manzanares Secades C, et al. Once-daily gentamicin dosing in neonates. Pediatr Infect Dis 1998;17:1169
101. Hayani K, Hatzopoulos F, Frank A, et al. Pharmacokinetics of once-daily dosing of gentamicin in neonates. J Pediatrics 1997;131:76-80
102. Tessin I, Bergmark J, Hiesche K, et al. Renal function of neonates during gentamicin treatment. Arch Dis Child 1982;57(10):758-60
103. Rajchgot P, Prober CG, Soldin S, et al. Aminoglycoside-related nephrotoxicity in the premature newborn. Clin Pharmacol Ther 1984;35(3):394-401
104. Kotze A, Bartel PR, Sommers DK. Once versus twice daily amikacin in neonates: prospective study on toxicity. J Paediatr Child Health 1999;35(3):283-6
105. Lietman S, Smith CR, Lipsky JJ, Lietman PS. Relationship between aminoglycoside-induced nephrotoxicity and auditory toxicity. 1979;15(6):780-2
106. Agarwal G. Original article comparison of once-daily versus twice-daily gentamicin. J Perinatol 2002;22:268-74
107. Mercado M, Brodsky N, McGuire M, Hurt H. Extended interval dosing of gentamicin in preterm infants. Am J Perinatol 2004;21(2):73-7
108. Isemann B, Kotagal U, Mashni S, et al. Optimal gentamicin therapy in preterm neonates includes loading doses and early monitoring. Ther Drug Monit 1996;18(5):549-55
109. Allen A, Mccracken H, Roeser RJ, Chrane DF. Ototoxicity in neonates treated with gentamicin and kanamycin: results of a four-year controlled follow-up Study. Pediatrics 1979;63:443
110. Langhendries J, Battisti O, Bertrand J, et al. Once-a-day administration of amikacin in neonates: assessment of nephrotoxicity and ototoxicity. Dev Pharmacol Ther 1993;20:220-30
111. Krishnan L, George S. Gentamicin therapy in preterms: A comparison of two dosage regimens. Indian Pediatrics 1997;34(12):1075-80
112. Kosalaraka P, Janthep P, Jirapradittha J, et al. Once versus twice daily dose of gentamicin therapy in Thai neonates. J Med Assoc Thailand 2004;87:372-6
113. Davidović-Plavšić B, Vujić T, Uletilović S, et al. Urinary activities of proximal tubule enzymes in neonates treated with gentamicin. J Med Biochem 2010;29(1):44-7
114. Abdel-Hady E, El Hamamsy M, Hedaya M, Awad H. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis. J Clin Pharm Ther 2011;36(1):45-52